newsfilter
← Latest News
GlobeNewswire·

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome

Amryt Receives Orphan Drug Designation from the FDA for Mycapssa® (oral octreotide) for the Treatment of Carcinoid Syndrome DUBLIN, Ireland, and Boston MA, July 14, 2022, Amryt (NASDAQ:AMYT), a global, commercial-stage biopharmaceutical company focus